Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07099404

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Assess the uptake of rubidium-82 in parathyroid adenomas.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Parathyroid Adenomas Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Hyperparathyroidism Hyperparathyroidism, Primary Neoplasms Neoplasms by Site Parathyroid Diseases Parathyroid Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Montreal Heart Institute, Montreal, Quebec, Canada

Loading trial locations.

About this study

Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.

The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18y
  • Ability to undergo imaging logistics
  • Ability to provide informed consent
  • Biochemical evidence of primary hyperparathyroidism
  • Documented parathyroid adenoma on prior 18F-fluorocholine imaging

Exclusion criteria

  • Normocalcemic primary hyperparathyroidism
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to undergo imaging logistics
  • Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

Treatment and study plan

PET/CT imaging with rubidium-82

Other

PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.

Other names: Rubidium-82, PET/CT

Primary outcomes

  1. Uptake pattern of rubidium-82 in parathyroid adenomas

    Time frame: 3 months

    Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Secondary outcomes

  1. Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas

    Time frame: 3 months

    Radioactive tracer uptake will be compared between Rudibium-82 and 18F-Fluorocholine. Uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Study contacts

Contact information is provided by the study sponsor or research team.

Matthieu Pelletier-Galarneau, MD MSc

CONTACT

[email protected]

514-376-3330 ext. 4418

Pelletier-Galarneau

CONTACT

Sponsors and collaborators

Lead sponsor

Matthieu Pelletier-Galarneau, MD MSc

Other

Registry information

Official study title

Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study

Acronym: PARAGON

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Aug 1, 2025
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.